CN113195530A - 抗体融合蛋白、制备方法及其应用 - Google Patents

抗体融合蛋白、制备方法及其应用 Download PDF

Info

Publication number
CN113195530A
CN113195530A CN201980083143.4A CN201980083143A CN113195530A CN 113195530 A CN113195530 A CN 113195530A CN 201980083143 A CN201980083143 A CN 201980083143A CN 113195530 A CN113195530 A CN 113195530A
Authority
CN
China
Prior art keywords
heavy chain
fusion protein
antibody
constant region
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980083143.4A
Other languages
English (en)
Other versions
CN113195530B (zh
Inventor
冯晓
王涛
金磊
郭洪瑞
刘爽
韩宁
梁阳秋
陈宇珩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GeneScience Pharmaceuticals Co Ltd
Original Assignee
GeneScience Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GeneScience Pharmaceuticals Co Ltd filed Critical GeneScience Pharmaceuticals Co Ltd
Publication of CN113195530A publication Critical patent/CN113195530A/zh
Application granted granted Critical
Publication of CN113195530B publication Critical patent/CN113195530B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)

Abstract

本发明属于药物领域，具体涉及抗体融合蛋白、制备方法及其应用。该抗体融合蛋白，表达量高，哺乳动物细胞293E中瞬转表达量100‑150mg/L；装配率高，正确装配率超过95％；亲和力高，单边抗体/融合蛋白和抗原结合KD值与阳性对照单克隆抗体/融合蛋白和抗原结合KD值相当；便于纯化，使用Protein A或Protein L一步纯化纯度即可达到95％以上，药效实验动物体内抑瘤率最高可达92％。

Description

PCT国内申请，说明书已公开。

Claims (22)

  1. PCT国内申请，权利要求书已公开。
CN201980083143.4A 2018-12-28 2019-12-26 抗体融合蛋白、制备方法及其应用 Active CN113195530B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811620872.2A CN111378044B (zh) 2018-12-28 2018-12-28 抗体融合蛋白、制备方法及其应用
CN2018116208722 2018-12-28
PCT/CN2019/128585 WO2020135556A1 (zh) 2018-12-28 2019-12-26 抗体融合蛋白、制备方法及其应用

Publications (2)

Publication Number Publication Date
CN113195530A true CN113195530A (zh) 2021-07-30
CN113195530B CN113195530B (zh) 2023-06-16

Family

ID=71129691

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811620872.2A Active CN111378044B (zh) 2018-12-28 2018-12-28 抗体融合蛋白、制备方法及其应用
CN201980083143.4A Active CN113195530B (zh) 2018-12-28 2019-12-26 抗体融合蛋白、制备方法及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201811620872.2A Active CN111378044B (zh) 2018-12-28 2018-12-28 抗体融合蛋白、制备方法及其应用

Country Status (7)

Country Link
US (1) US20220073620A1 (zh)
EP (1) EP3904381A1 (zh)
KR (1) KR20210107747A (zh)
CN (2) CN111378044B (zh)
AU (1) AU2019416503A1 (zh)
CA (1) CA3125120A1 (zh)
WO (1) WO2020135556A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112433055A (zh) * 2020-11-04 2021-03-02 上海药明生物技术有限公司 一种基于报告基因方法检测pvrig抗体的生物学活性的方法
WO2022174451A1 (zh) * 2021-02-22 2022-08-25 浙江道尔生物科技有限公司 一种具有抗癌活性的多结构域融合蛋白
CN112961250B (zh) * 2021-03-01 2023-06-06 长春金赛药业有限责任公司 抗体融合蛋白及其应用
EP4357366A1 (en) * 2021-06-18 2024-04-24 Hangzhou Sumgen Biotech Co., Ltd. Bispecific fusion protein

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103068847A (zh) * 2010-08-24 2013-04-24 罗切格利卡特公司 可活化的双特异性抗体
CN104271601A (zh) * 2012-05-31 2015-01-07 霍夫曼-拉罗奇有限公司 使用pd-1轴结合拮抗剂和vegf拮抗剂治疗癌症的方法
CN105461808A (zh) * 2015-12-24 2016-04-06 长春金赛药业有限责任公司 单克隆抗体及其应用
CN106103482A (zh) * 2014-01-23 2016-11-09 瑞泽恩制药公司 针对pd‑l1的人抗体
CN106397598A (zh) * 2016-02-23 2017-02-15 上海交通大学 多价多特异性抗体及免疫杂合蛋白的表达和制备方法
CN106892980A (zh) * 2017-01-25 2017-06-27 长春金赛药业有限责任公司 抗vegfr2单克隆抗体及其应用
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
CN108250296A (zh) * 2018-01-17 2018-07-06 长春金赛药业股份有限公司 全人源抗人pd-l1单克隆抗体及其应用
CN108623691A (zh) * 2017-03-17 2018-10-09 北京比洋生物技术有限公司 IgG样长效免疫融合蛋白及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
BRPI0011407B8 (pt) 1999-06-08 2021-05-25 Regeneron Pharma molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão
KR20020093029A (ko) 2000-04-11 2002-12-12 제넨테크, 인크. 다가 항체 및 그의 용도
US20050008649A1 (en) * 2003-06-02 2005-01-13 University Of Miami Chimeric molecules and methods of use
CN104159926B (zh) * 2011-12-01 2019-02-01 圆祥生命科技有限公司 补体和vegf途径的蛋白质抑制剂及其使用方法
WO2015058048A1 (en) * 2013-10-18 2015-04-23 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
WO2015109898A1 (zh) * 2014-01-24 2015-07-30 上海恒瑞医药有限公司 VEGF与PDGFRβ双特异性融合蛋白及其用途
CA3019921A1 (en) * 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
US20190177439A1 (en) * 2016-08-16 2019-06-13 Epimab Biotherapeutics, Inc. Monovalent Asymmetric Tandem Fab Bispecific Antibodies
UA128306C2 (uk) * 2017-05-12 2024-06-05 Джянгсу Хенгруй Медісін Ко., Лтд. ЗЛИТІ ПРОТЕЇНИ, ЯКІ МІСТЯТЬ РЕЦЕПТОР TGF-<font face="Symbol">b</font>, І ЇХ ФАРМАЦЕВТИЧНЕ ЗАСТОСУВАННЯ

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103068847A (zh) * 2010-08-24 2013-04-24 罗切格利卡特公司 可活化的双特异性抗体
CN104271601A (zh) * 2012-05-31 2015-01-07 霍夫曼-拉罗奇有限公司 使用pd-1轴结合拮抗剂和vegf拮抗剂治疗癌症的方法
CN106103482A (zh) * 2014-01-23 2016-11-09 瑞泽恩制药公司 针对pd‑l1的人抗体
CN105461808A (zh) * 2015-12-24 2016-04-06 长春金赛药业有限责任公司 单克隆抗体及其应用
CN106397598A (zh) * 2016-02-23 2017-02-15 上海交通大学 多价多特异性抗体及免疫杂合蛋白的表达和制备方法
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
CN106892980A (zh) * 2017-01-25 2017-06-27 长春金赛药业有限责任公司 抗vegfr2单克隆抗体及其应用
CN108623691A (zh) * 2017-03-17 2018-10-09 北京比洋生物技术有限公司 IgG样长效免疫融合蛋白及其应用
CN108250296A (zh) * 2018-01-17 2018-07-06 长春金赛药业股份有限公司 全人源抗人pd-l1单克隆抗体及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NILIANG QIAN 等: "Construction, expression, purification, and characterization of a dual-targeting PD-1/VEGF-A fusion protein (P-V)", 《PROTEIN EXPRESSION AND PURIFICATION》 *
YOUNG WHA KOH等: "PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma", 《ANNALS OF HEMATOLOGY》 *
王倩: "PD-1-VEGF多靶向Fc融合蛋白PVP的表达、纯化及初步功能研究", 《中国优秀博硕士学位论文全文数据库(硕士)医药卫生科技辑》 *

Also Published As

Publication number Publication date
WO2020135556A1 (zh) 2020-07-02
AU2019416503A1 (en) 2021-07-22
CA3125120A1 (en) 2020-07-02
CN111378044A (zh) 2020-07-07
CN113195530B (zh) 2023-06-16
CN111378044B (zh) 2022-07-15
US20220073620A1 (en) 2022-03-10
EP3904381A1 (en) 2021-11-03
KR20210107747A (ko) 2021-09-01

Similar Documents

Publication Publication Date Title
CN107001468B (zh) Cd3结合结构域
JP6385357B2 (ja) 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途
TWI564306B (zh) 雙特異性抗體
CN113195530B (zh) 抗体融合蛋白、制备方法及其应用
US20160009824A1 (en) Tetravalent bispecific antibodies
KR20220071263A (ko) Cd3을 표적으로 하는 항체, 이중 특이성 항체 및 이의 용도
JP7365654B2 (ja) 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体
JP2023159379A (ja) Ｐｄ－１とｖｅｇｆを標的とした四価二重特異性抗体、その製造方法および用途
JP2024504124A (ja) 新規の抗グレムリン１抗体
WO2022218380A1 (zh) 靶向bcma的多特异性抗体
JP7078237B1 (ja) 抗ｔｓｐａｎ８－抗ｃｄ３二重特異性抗体及び抗ｔｓｐａｎ８抗体
JP2022537823A (ja) 共有結合型多重特異性抗体
CN113490690A (zh) 异源二聚体融合蛋白
CN116874606B (zh) 一种靶向trop2和cd3的双特异性抗体及其制备方法与应用
WO2024188319A1 (zh) 抗muc17、cd3和cd28三特异性抗体
WO2023199927A1 (ja) がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｔｓｐａｎ８－抗ｃｄ３二重特異性抗体の使用
WO2023219121A1 (ja) 抗ｔａａ－抗ｃｄ３多重特異性抗体
WO2019072274A1 (zh) 一种激动型4-1bb单克隆抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant